TRCT
RPRX icon

Tower Research Capital (TRC)’s Royalty Pharma RPRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.6K Sell
992
-4,678
-83% -$243K ﹤0.01% 2645
2026
Q1 		$272K Sell
5,670
-5,177
-48% -$227K 0.01% 1376
2025
Q4 		$419K Sell
10,847
-1,029
-9% -$39.2K 0.01% 925
2025
Q3 		$419K Buy
11,876
+11,041
+1,322% +$400K 0.01% 984
2025
Q2 		$30.1K Sell
835
-1,800
-68% -$59.6K ﹤0.01% 3397
2025
Q1 		$82K Sell
2,635
-16,851
-86% -$534K ﹤0.01% 1885
2024
Q4 		$497K Sell
19,486
-309
-2% -$8.19K 0.01% 1065
2024
Q3 		$560K Sell
19,795
-10,053
-34% -$278K 0.01% 802
2024
Q2 		$787K Buy
29,848
+26,646
+832% +$739K 0.01% 949
2024
Q1 		$97.2K Sell
3,202
-14,653
-82% -$432K ﹤0.01% 1834
2023
Q4 		$502K Sell
17,855
-20,588
-54% -$566K 0.01% 1366
2023
Q3 		$1.04M Buy
38,443
+36,857
+2,324% +$1.09M 0.03% 524
2023
Q2 		$48.8K Sell
1,586
-387
-20% -$13.1K ﹤0.01% 2603
2023
Q1 		$71K Sell
1,973
-11,842
-86% -$439K ﹤0.01% 2190
2022
Q4 		$546K Buy
13,815
+11,035
+397% +$461K 0.02% 653
2022
Q3 		$112K Sell
2,780
-3,465
-55% -$148K ﹤0.01% 2467
2022
Q2 		$263K Buy
6,245
+356
+6% +$14.6K 0.01% 1580
2022
Q1 		$229K Sell
5,889
-10,109
-63% -$397K ﹤0.01% 1635
2021
Q4 		$638K Buy
15,998
+14,438
+926% +$561K 0.01% 951
2021
Q3 		$57K Sell
1,560
-27,047
-95% -$1.05M ﹤0.01% 2844
2021
Q2 		$1.17M Buy
28,607
+24,136
+540% +$1.03M 0.03% 549
2021
Q1 		$195K Buy
4,471
+2,414
+117% +$114K ﹤0.01% 2033
2020
Q4 		$103K Buy
2,057
+1,558
+312% +$66.1K ﹤0.01% 2318
2020
Q3 		$21K Buy
+499
New +$21.4K ﹤0.01% 3852

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s RPRX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Royalty Pharma (RPRX) stake by 83% in Q2 2026, selling an estimated $243K and leaving 992 shares worth $55.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2645.

Tower Research Capital (TRC) first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.17M in Q2 2021. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Tower Research Capital (TRC) held 992 shares of Royalty Pharma worth $55.6K as of Q2 2026.
  • Tower Research Capital (TRC) sold 4,678 Royalty Pharma shares in Q2 2026, an estimated $243K.
  • Royalty Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2645 holding.
  • Tower Research Capital (TRC) first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Royalty Pharma position peaked at $1.17M in Q2 2021.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.